PPIL2: A Potential Drug Target and Biomarker for Chronic Pain

Target Name: PPIL2

NCBI ID: G23759

PPIL2

PPIL2: A Potential Drug Target and Biomarker for Chronic Pain

Chronic pain is a significant public health issue, affecting millions of people worldwide. The World Health Organization (WHO) estimates that approximately 50% of the global population experiences chronic pain, with costs associated with chronic pain reaching $600 billion annually. Chronic pain can be caused by various conditions, including neurological and psychiatric disorders, as well as injuries and diseases. While several treatments have been developed to manage chronic pain, the availability of effective therapies remains a major challenge.

PPIL2, a protein that resembles cyclophilin, has been identified as a potential drug target and biomarker for chronic pain. In this article, we will explore the biology of PPIL2 and its potential as a drug target and biomarker for chronic pain.

Biochemistry and Proteomics of PPIL2

PPIL2 (Proteolytic processing of IP3-like protein 2) is a 21-kDa protein that is expressed in various tissues and cells, including brain, muscle, and peripheral tissues. It is characterized by a unique N-terminal domain that contains a farnesylated cysteine residue, which is important for protein stability and localization in the membrane. PPIL2 is also known as Cyp-60, due to its cytoplasmic distribution and the presence of a unique 60 amino acid residue in its N-terminus.

PPIL2 has been shown to play a role in various cellular processes, including cell signaling, neurotransmitter release, and inflammation. It is involved in the regulation of ion channels, such as the Na+/K+-ATPase and the Ca2+/Mg2+-ATPase, which are involved in the regulation of intracellular signaling pathways. PPIL2 has also been shown to play a role in the regulation of pain perception and neuroinflammation.

Drug Target Potential

The potential drug targets for PPIL2 are based on its unique structure and the various functions it has been shown to play in cellular processes. One potential drug target is the regulation of pain perception, as PPIL2 has been shown to play a role in the regulation of pain signaling in the brain. Another potential drug target is the regulation of neuroinflammation, as PPIL2 has been shown to play a role in the regulation of inflammation in various tissues.

Biomarker Potential

PPIL2 has also been identified as a potential biomarker for chronic pain due to its expression in various tissues and its ability to detect pain in a controlled manner. PPIL2 can be used as a therapeutic target to reduce pain perception and improve the quality of life in individuals with chronic pain.

Conclusion

In conclusion, PPIL2 is a protein that has potential as a drug target and biomarker for chronic pain. Its unique structure and various functions, including the regulation of pain perception and neuroinflammation, make it an attractive target for drug development. Further research is needed to fully understand the biology of PPIL2 and its potential as a drug and biomarker for chronic pain.

Protein Name: Peptidylprolyl Isomerase Like 2

Functions: Has a ubiquitin-protein ligase activity acting as an E3 ubiquitin protein ligase or as an ubiquitin-ubiquitin ligase promoting elongation of ubiquitin chains on substrates. By mediating 'Lys-48'-linked polyubiquitination of proteins could target them for proteasomal degradation (PubMed:11435423). May also function as a chaperone, playing a role in transport to the cell membrane of BSG/Basigin for instance (PubMed:15946952). Probable inactive PPIase with no peptidyl-prolyl cis-trans isomerase activity (PubMed:20676357). As a component of the minor spliceosome, involved in the splicing of U12-type introns in pre-mRNAs (Probable)

The "PPIL2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PPIL2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets